Semaglutide at 6 months: STEP trial data

Posts about losing 80 or 90 pounds in six months on semaglutide appear regularly on Reddit and other forums. The numbers are striking, and they raise a fair question: is that kind of result typical, or an outlier? The clinical trial data gives us a clearer picture than any single anecdote can.

In the STEP 4 trial, participants who completed a 20-week run-in on semaglutide 2.4 mg weekly had already lost a mean of 10.6% of their body weight before randomisation^[1]. That 20-week mark is roughly the five-month point, and it tells us that a large share of early weight loss happens during dose escalation and the first months at a maintenance dose.

What the STEP trials show at six months and beyond

The STEP programme is the largest body of randomised evidence on semaglutide 2.4 mg for weight management. STEP 1 enrolled 1,961 adults with obesity or overweight plus at least one weight-related condition (excluding diabetes). At 68 weeks, the semaglutide group lost a mean of 14.9% of body weight versus 2.4% on placebo^[2]. While the trial did not publish a standalone 6-month data point, the weight curve shows that most of the loss occurs in the first 30 to 40 weeks, with the rate of loss slowing markedly after that.

STEP 5 extended the observation to two full years. At 104 weeks, mean weight loss on semaglutide was 15.2% versus 2.6% on placebo^[3]. The trajectory matters here: participants lost weight rapidly in the first six to eight months, then entered a slower phase where weight stabilised or continued to decline at a much lower rate. That plateau is not a failure. It reflects the body reaching a new energy equilibrium on the drug.

The plateau is expected, not a problem

If you are six months into treatment and your weight loss has stalled, the trial data says that is normal. The STEP 5 weight curve flattens between months seven and ten for most participants. The body adjusts its metabolic rate as weight drops, appetite regulation recalibrates, and the pace of loss slows. Some people interpret this as the drug "stopping working" when it is actually doing exactly what the trials predict.

Whether a dose adjustment makes sense at a plateau is a clinical decision. The STEP trials used a fixed escalation (0.25 mg up to 2.4 mg weekly), and results reflect outcomes at that target dose. If you have not yet reached the maintenance dose, there may be room for titration. If you have, changing the dose is a conversation for your prescriber.

What happens if you stop

The STEP 1 extension followed participants for one year after treatment ended. Those who had lost a mean of 17.3% of their body weight on semaglutide regained about two-thirds of that loss within 52 weeks of stopping^[4]. Cardiometabolic improvements (blood pressure, lipids, HbA1c) also reversed. The clinical implication is straightforward: semaglutide treats obesity the way a blood pressure medication treats hypertension. Stopping the drug tends to bring the condition back.

STEP 4 showed the same pattern from a different angle. Participants who switched from semaglutide to placebo at week 20 regained 6.9% of body weight by week 68, while those who continued lost an additional 7.9%^[1]. The gap between the two groups at week 68 was 14.8 percentage points.

Nutritional risks during rapid weight loss

Losing a large amount of weight in a short period, whether on semaglutide or otherwise, carries nutritional risks that community posts rarely discuss. A 2026 review in Clinical Nutrition ESPEN found that lean mass loss is a consistent concern during GLP-1 receptor agonist therapy and recommended daily protein intakes of at least 1.2 g/kg body weight (up to 1.6 g/kg in appropriate adults without chronic kidney disease), with structured resistance training^[5]. The same review flagged baseline deficiencies in vitamin D, B12, iron, folate, zinc, and thiamine as common in people with obesity, noting that these may worsen when appetite suppression reduces total food intake.

A 2025 case series reported that in clinical trials, lean tissue loss typically makes up 26% to 40% of total weight lost on GLP-1 and GIP/GLP-1 agonists^[6]. The patients in that case series who combined the medication with resistance training three to five days per week and high protein intake (up to 1.7 g/kg body weight) preserved or even gained lean mass while losing fat. The sample was small (three patients), but the direction is consistent with the broader sports-nutrition literature on protein and resistance training during caloric deficit.

Practical takeaways on nutrition

If you are losing weight rapidly on semaglutide, the available evidence points to three things worth discussing with your healthcare provider: getting enough protein despite reduced appetite, incorporating resistance exercise to preserve muscle, and monitoring key micronutrients (especially if nausea or vomiting further limits what you eat). A registered dietitian familiar with GLP-1 therapy can help structure this. For more on semaglutide's mechanism and prescribing status, see our semaglutide overview.

Community stories versus clinical evidence

Reddit posts showing dramatic results are motivating but not representative. Trials report means across hundreds of participants, including modest responders and dropouts. A person losing 90 pounds in six months may be a high responder, may have started at a very high baseline weight, or may have made lifestyle changes not captured in a short post. That does not invalidate their experience, but you should not calibrate your own expectations to it.

The trial-level expectation for six months on semaglutide 2.4 mg is roughly 10% to 12% body weight loss, based on the STEP 4 run-in data and the trajectory curves from STEP 1 and STEP 5. Some people will exceed that. Some will fall short. Both outcomes are within the range the trials document. For a broader look at how semaglutide compares to other weight-loss medications, see our coverage of the GLP-1 receptor agonist class.

When to talk to your prescriber

If weight loss has stalled early, if persistent GI side effects limit your ability to eat, if you are losing weight faster than expected and feeling fatigued, or if you are considering changing your dose on your own: speak with the clinician who prescribed the medication. Dose adjustments and nutritional interventions depend on your individual history.

What we do not yet know

The STEP trials ran for one to two years. We do not have five-year data on continuous semaglutide use for weight management. We do not know whether the plateau represents a true steady state or whether very slow loss continues beyond year two. We also lack large-scale data on the long-term effects of lean mass loss during rapid weight reduction. These are open questions that future trials and real-world registries will need to answer.

This article is for educational purposes and does not constitute medical advice. If you are considering semaglutide or are already using it, consult a qualified healthcare professional about your individual situation.